Regional research still hampered by cross-border differences
pharmafile | May 8, 2008 | Feature | Research and Development |Â Â Europe, clinical trials, researchÂ
Related Content
Most advanced breast cancer patients treated in community settings, Phesi study finds
Most patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer are treated in community settings …
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison
Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose …
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two …
